| Customization: | Available |
|---|---|
| Application: | Surgery |
| Usage Mode: | Injection |
|
Still deciding? Get samples of US$ 500/Bag
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Drug name:
Peritoneal dialysis solution(lactate)
Components:
This product is a compound formulation, containing 15g (or 25g, 42.5g) of glucose, 5.38g of sodium chloride, 0.26g of calcium chloride, 0.051g of magnesium chloride, and 4.48g of sodium lactate per 1000ml.
| Specifications: |
|
concentration:1.5%, 2.5% , 4.25% ; specifications:1000ml, 1500ml, 2000ml, 2500ml, 3000ml |
| Usage and dosage: |
| 3-5 bags/day |
| Indications: |
| This product is suitable for chronic renal failure patients who require continuous ambulatory peritoneal dialysis (CAPD) treatment due to ineffective non dialysis treatment. |
Acute renal failure: If there are no contraindications, peritoneal dialysis can be chosen
Chronic renal failure: peritoneal dialysis is feasible without absolute contraindications
Priority should be given to peritoneal dialysis in the following situations
1. Infants and children;
2. Poor vascular conditions or repeated arteriovenous fistula failure;
3. Coagulation dysfunction with obvious bleeding or bleeding tendency;
4. The residual kidney function is good;
5. Those who prefer home treatment or need to work or attend school during the day;
6. Patients in rural areas and remote areas far from central cities
toxic diseases
For patients with acute drug and toxin poisoning, especially those with contraindications to hemodialysis or those who undergo hemodialysis unconditionally, peritoneal dialysis can be used for treatment
others
1. Adjuvant treatment for liver diseases such as congestive heart failure,
2. acute pancreatitis,
3. hepatic encephalopathy, and hyperbilirubinemia;
4. Intraperitoneal administration and nutritional support
Founded in May 1998, Huaren Pharmaceutical is a modern pharmaceutical and health industry group integrating R&D, production and sales, focusing on medicine, health, medical equipment and medical services.
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.
After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".
Taking innovation as the soul of development, in recent years, the company actively grasps the strategic development opportunities, focuses on the treatment direction of nephrology, respiratory medicine, precision and anaesthesiology, as well as the screening of new varieties such as large-volume preparations, and targets the world-class enterprises at home and abroad, continuously increases research and development investment, enrich the research and development pipeline, enrich the product line, and enhance the ability of sustainable development. By the end of 2023, Huayen Pharmaceutical and its subsidiaries had obtained 508 authorized patents, including 103 invention patents. Among them, the wholly-owned subsidiary Xingxing Pharmaceutical is one of the 50 designated manufacturers of class II psychotropic drug raw materials in China. Among them, the market share of peritoneal dialysate products ranked first among domestic brands.
Through more than 20 years of exploration and practice, the company has won a series of honors such as "National key technology transformation 'double high and one Excellent' project", "National Intellectual Property Advantage Demonstration Enterprise", "Shandong Pharmaceutical Industry Excellence Enterprise in the 60th anniversary of the founding of the People's Republic of China", "Shandong Quality Management Award", "Shandong famous Brand Product", "Shandong Executive Brand Cultivation Enterprise", "Respiratory system outstanding product brand" and so on. In 2020, the company won the honorary title of "2020 National market Quality Credit AA level (customer satisfaction Enterprise)" issued by the China Quality Association. In 2022, the company won the "May Day Labor Award of Shandong Province". In 2024, it was ranked 71 in the "Top 100 Chinese Pharmaceutical Industry" for five consecutive years.
| Q1- Which payment terms are you accept? A: T/T or lrrevocable L/C at sight. |
| Q2- How do you ship the order normally? A: We can ship goods by sea, by train or by air. |
| Q3- Can the packaging be customized? A: Yes, we accept packaging customization service. |
){kind=link}